RecruitingNCT07383025
Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan
Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy (oHCM) in Japan
Sponsor
Bristol-Myers Squibb
Enrollment
200 participants
Start Date
May 21, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) receiving mavacamten in Japan
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- • All obstructive hypertrophic cardiomyopathy (oHCM) patients who initiate treatment with Mavacamten of the approved indications at medical institutions in Japan during enrollment period will be enrolled in this regulatory post-marketing surveillance (PMS) study
Exclusion Criteria1
- • Participants receiving Mavacamten for an off-label indication will be excluded from this PMS study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGMavacamten
According to the product label
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07383025